Case–controlled identification of colorectal cancer based on proteomic profiles and the potential for screening. (November 2014)

• Record Type: Journal Article
• Authors: Huijbers, A.; Mesker, W. E.; Mertens, B. J.; Bladergroen, M. R.; Deelder, A. M.; van der Burgt, Y. E. M.; Tollenaar, R. A. E. M.
• Is Part Of: Colorectal disease. Volume 16:Number 11(2014)
• Page Start: 907
• Page End: 913
• Publication Date: 2014-11
• Subjects: Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.12782
• Languages: English
• ISSNs: 1462-8910

Abstract

<abstract abstract-type="main" id="codi12782-abs-0001"> <title>Abstract</title> <sec id="codi12782-sec-0001" sec-type="section"> <title>Aim</title> <p>Colorectal cancer (CRC) screening programmes detect early cancers but unfortunately have limited sensitivity and specificity. Mass spectrometry‐based determination of serum peptide and protein profiles provides a new approach for improved screening.</p> </sec> <sec id="codi12782-sec-0002" sec-type="section"> <title>Method</title> <p>Serum samples were obtained from 126 CRC patients before treatment and 277 control individuals. An additional group of samples from 50 CRC patients and 82 controls was used for validation. Peptide and protein enrichments were carried out using reverse‐phase C18 and weak‐cation exchange magnetic beads in an automated solid‐phase extraction and spotting procedure. Profiles were acquired on a matrix‐assisted laser desorption/ionization time‐of‐flight system. Discriminant rules using logistic regression were calibrated for the peptide and protein signatures separately, followed by combining the classifications to obtain double cross‐validated predicted class probabilities. Results were validated on an identical patient set.</p> </sec> <sec id="codi12782-sec-0003" sec-type="section"> <title>Results</title> <p>A discriminative power was found for patients with CRC representative for all histopathological stages compared with controls with an area under the curve of 0.95 in the test set (0.93 for the validation set) and with a high specificity (94–95%).</p> </sec> <sec id="codi12782-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The study has shown that a serum peptide and protein biomarker signature can be used to distinguish CRC patients from healthy controls with high discriminative power. This relatively simple and cheap test is promising for CRC screening.</p> </sec> </abstract>